Sanofi India Limited reported its financial results for the quarter ended September 30, 2025, showing steady operational performance.
Revenue from operations stood at ₹475.4 crore, compared to ₹524 crore in the same quarter last year, reflecting a 9.3% year-on-year decline.
Despite softer revenue, the company maintained strong profitability, supported by cost optimization and improved efficiency across key segments. Net profit for the quarter came in at ₹76 crore, as against ₹82.2 crore in Q2 FY24.
EBITDA rose 12% year-on-year to ₹134 crore, compared to ₹120 crore in the same quarter last year. The company’s EBITDA margin improved sharply to 28.23%, up from 22.84% a year ago, reflecting better operational efficiency and cost control.
In the meantime, as of 1:37 PM, Sanofi India shares were trading 0.076% lower at Rs 4,744.80.
Disclaimer: This article is for informational purposes only. It is not intended to be investment advice or a recommendation to buy or sell any stock. Readers are advised to consult their financial advisor before making any investment decisions.
